Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Zacks Rating on Rockwell Medical, Inc. - News Watch International |
 |
 |
|
As much as 4 analysts have advised buy on Rockwell Medical, Inc. (NASDAQ:RMTI) with an average broker rating of 2. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral on the company. Rockwell Medical, Inc. (NASDAQ:RMTI) shares are expected to touch $16.25 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 9.18. The target price could hit $26 on the higher end and $4 on the lower end. The company has received recommendation from many analysts. 3 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 5.03% or 0.67 points on Monday and made its way into the gainers of the day. After trading began at $13.6 the stock was seen hitting $14.03 as a peak level and $13.33 as the lowest level. The stock ended up at $13.99. The daily volume was measured at 1,102,168 shares. The 52-week high of the share price is $13.35 and the 52-week low is $8.095. The company has a market cap of $702 million. Several Brokerage firms have commented on company shares. Oppenheimer initiates coverage on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Outperform on the counter. In a recent information released to the investors, Oppenheimer the price target of $24 per share. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A REPLY Cancel reply |
